Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 695Neoplasms 613Prostatic Neoplasms 315Lung Neoplasms 308Colorectal Neoplasms 282Carcinoma, Non-Small-Cell Lung 254Pancreatic Neoplasms 178Carcinoma, Hepatocellular 168Stomach Neoplasms 139Multiple Myeloma 127Ovarian Neoplasms 120Melanoma 118Colonic Neoplasms 112Brain Neoplasms 108Hematologic Neoplasms 107Head and Neck Neoplasms 106Urinary Bladder Neoplasms 103Leukemia, Myeloid, Acute 102Esophageal Neoplasms 101Disease 100Uterine Cervical Neoplasms 89Neoplasm Metastasis 89Liver Neoplasms 88Rectal Neoplasms 85Lymphoma 84Precursor Cell Lymphoblastic Leukemia-Lymphoma 83Endometrial Neoplasms 76Carcinoma, Renal Cell 73Leukemia 63Recurrence 62

Interventions

taletrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Non-small Lung Cancer × 1 year × Clear all
NCT07199010 2025-09-30

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting
50 enrolled
Thoracic

Non-small Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡